Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3810.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 2,892,221). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| CTXR | VCSH | |
|---|---|---|
Market Cap | $13.62M | $51.90B |
Volume | 132,438 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $80.20 |
52-Week Low | $0.48 | $77.03 |
Typical Hold Time | 17 Days | 52 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
VCSH trades at $77.30 with minimal daily movement (+0.04%). The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights VCSH's competitive 4.5-4.8% dividend yield and low 0.03% expense ratio, though credit spreads remain tight. The ETF's short 2.7-year duration provides some protection against rising rates.
VCSH offers stable income exposure to investment-grade corporate bonds but faces headwinds from tight credit spreads and limited price appreciation potential. The fund's low duration minimizes interest rate risk, making it suitable for conservative investors seeking yield above Treasury alternatives, though corporate credit risk remains a consideration in economic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
